JP2012504604A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504604A5 JP2012504604A5 JP2011530048A JP2011530048A JP2012504604A5 JP 2012504604 A5 JP2012504604 A5 JP 2012504604A5 JP 2011530048 A JP2011530048 A JP 2011530048A JP 2011530048 A JP2011530048 A JP 2011530048A JP 2012504604 A5 JP2012504604 A5 JP 2012504604A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkenyl
- alkynyl
- con
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19483108P | 2008-10-01 | 2008-10-01 | |
| US61/194,831 | 2008-10-01 | ||
| PCT/US2009/005407 WO2010039237A1 (en) | 2008-10-01 | 2009-10-01 | Compounds for inflammation and immune-related uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504604A JP2012504604A (ja) | 2012-02-23 |
| JP2012504604A5 true JP2012504604A5 (enExample) | 2012-11-22 |
Family
ID=41263687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530048A Pending JP2012504604A (ja) | 2008-10-01 | 2009-10-01 | 炎症および免疫関連使用のための化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8314130B2 (enExample) |
| EP (1) | EP2350064A1 (enExample) |
| JP (1) | JP2012504604A (enExample) |
| AU (1) | AU2009300317A1 (enExample) |
| CA (1) | CA2739322A1 (enExample) |
| TW (1) | TW201026693A (enExample) |
| WO (1) | WO2010039237A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| US8404672B2 (en) | 2009-01-23 | 2013-03-26 | Bristol-Meyers Squibb Company | Substituted heterocyclic compounds |
| US8354398B2 (en) | 2009-01-23 | 2013-01-15 | Bristol-Myers Squibb Company | Substituted isoxazole compounds |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP2013525448A (ja) * | 2010-04-27 | 2013-06-20 | カルシメディカ,インク. | 細胞内カルシウムを調節する化合物 |
| WO2011139489A2 (en) | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| MX337711B (es) | 2010-08-27 | 2016-03-15 | Calcimedica Inc | Compuestos que modulan el calcio intracelular. |
| SG192176A1 (en) * | 2011-01-28 | 2013-08-30 | 4Sc Discovery Gmbh | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation |
| ES2660996T3 (es) * | 2011-05-03 | 2018-03-27 | PRCL Research Inc. | Compuestos para la inflamación y usos relacionados con el sistema inmunitario |
| WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| ES3033759T3 (en) | 2015-02-27 | 2025-08-07 | Calcimedica Inc | Pancreatitis treatment |
| JP6738575B2 (ja) | 2015-08-07 | 2020-08-12 | カルシメディカ,インク. | 脳卒中および外傷性脳損傷の処置のためのcracチャネル阻害剤の使用 |
| WO2019054430A1 (ja) * | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | 芳香族複素環を有するアミド化合物 |
| CN113557020A (zh) | 2018-09-14 | 2021-10-26 | 瑞真药业公司 | 包含crac抑制剂和皮质类固醇的组合物及其使用方法 |
| TWI885039B (zh) | 2020-01-13 | 2025-06-01 | 美商邊際分析公司 | 經取代吡唑并嘧啶及其用途 |
| CN118084860A (zh) * | 2024-02-06 | 2024-05-28 | 中国药科大学 | 芳酰胺类化合物及其药物组合物和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| US6451820B1 (en) * | 2000-03-23 | 2002-09-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents |
| HUP0401160A3 (en) | 2001-08-13 | 2008-01-28 | Janssen Pharmaceutica Nv | 2,4,5-trisubstituted thiazolyl derivatives having antiinflammatory activity, process for their preparation and pharmaceutical compositions containing them |
| KR100979988B1 (ko) | 2001-08-13 | 2010-09-03 | 얀센 파마슈티카 엔.브이. | 2-아미노-4,5-삼치환 티아졸릴 유도체 |
| EP1846372B1 (en) * | 2005-01-07 | 2014-04-16 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2006081389A1 (en) | 2005-01-25 | 2006-08-03 | Synta Pharmaceuticals Corp. | Thiophene compounds for inflammation and immune-related uses |
| CA2639913A1 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceutical Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
| JP5511664B2 (ja) | 2007-08-01 | 2014-06-04 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のための複素環−アリール化合物 |
| JP5431323B2 (ja) * | 2007-08-01 | 2014-03-05 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のためのピリジン化合物 |
-
2009
- 2009-10-01 EP EP09789388A patent/EP2350064A1/en not_active Withdrawn
- 2009-10-01 CA CA2739322A patent/CA2739322A1/en not_active Abandoned
- 2009-10-01 US US12/572,103 patent/US8314130B2/en not_active Expired - Fee Related
- 2009-10-01 TW TW098133371A patent/TW201026693A/zh unknown
- 2009-10-01 JP JP2011530048A patent/JP2012504604A/ja active Pending
- 2009-10-01 AU AU2009300317A patent/AU2009300317A1/en not_active Abandoned
- 2009-10-01 WO PCT/US2009/005407 patent/WO2010039237A1/en not_active Ceased
-
2012
- 2012-07-19 US US13/552,755 patent/US20130165451A9/en not_active Abandoned
-
2013
- 2013-12-17 US US14/108,864 patent/US20140107132A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504604A5 (enExample) | ||
| JP2012504605A5 (enExample) | ||
| JP2010509342A5 (enExample) | ||
| CA2669695A1 (en) | Tetrahydropyridinyl compounds for inflammation and immune-related uses | |
| JP2012504603A5 (enExample) | ||
| JP2010535218A5 (enExample) | ||
| JP2011525915A5 (enExample) | ||
| CN107592864B (zh) | 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮 | |
| JP2019163290A5 (enExample) | ||
| AU2008287799B2 (en) | Method for producing pyripyropene derivative and production intermediate thereof | |
| AU2019260159B2 (en) | HPK1 inhibitors, preparation method and application thereof | |
| JP2011016800A5 (enExample) | ||
| JP2010535214A5 (enExample) | ||
| JP2015502387A5 (enExample) | ||
| NZ603427A (en) | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) | |
| WO2017218580A1 (en) | Synthetic methods for the preparation of nicotinamide riboside and related compounds | |
| CA2796872A1 (en) | Novel synthesis for thiazolidinedione compounds | |
| JP2009530283A5 (enExample) | ||
| HRP20211151T1 (hr) | Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama | |
| US20190202834A1 (en) | Baricitinib intermediate, method for forming baricitinib intermediate, and method for preparing baricitinib or pharmaceutically acceptable salt thereof | |
| JP2015516968A5 (enExample) | ||
| JP2018502083A5 (enExample) | ||
| JP2025526425A (ja) | 抗体薬物複合体に適した毒素分子 | |
| EP3344634B1 (de) | (meth)acrylatgruppen aufweisende organosiliciumverbindungen und ein verfahren zu ihrer herstellung | |
| JP2008508199A (ja) | マスキングされたイソシアネート基を有するオルガノ珪素化合物 |